Bisphosphonates have been extensively studied in the adjuvant setting as a host-directed therapy to reduce the risk of breast-cancer relapse. The Early Breast Cancer Trialists' Collaborative Group (EBCTCG) patient-level meta-analysis of adjuvant bisphosphonates, which included 18 776 women with breast cancer, showed a reduction in breast-cancer-associated death among postmenopausal women (hazard ratio [HR] 0·82, 95% CI 0·73–0·93). This outcome was mainly due to the reduction in bone recurrence. Thus, several guidelines have included zoledronic acid and clodronic acid as adjuvant treatments for breast cancer in postmenopausal women.

中文翻译：

---

唑来膦酸佐剂治疗乳腺癌：并非所有人

双膦酸盐已在辅助治疗中作为宿主定向疗法进行了广泛研究，以降低乳腺癌复发的风险。早期乳腺癌研究者协作组（EBCTCG）对双膦酸盐类药物进行辅助治疗的患者水平荟萃分析（包括18 776名乳腺癌女性）显示，绝经后妇女与乳腺癌相关的死亡减少（危险比[HR] 0 ·82，95％CI 0·73-0·93）。该结果主要归因于骨复发的减少。因此，一些指南包括唑来膦酸和氯膦酸作为绝经后妇女乳腺癌的辅助治疗方法。